- Symptoms and diagnosis
- Usage examples
- Medicinal plants
- Frequent searches
- Medical search
- Health topics
- Healthy weight
- Medical dictionary
- Health sites
- Questions and answers
|Medical Marvels at New York Presbyterian Hospital: Man battles VHL disease|
Manuel Greco has Von Hippel-Lindau disease. It's a rare condition that causes tumors to grow in certain parts of the body. Most of the tumors are benign but they often grow back after being removed. Manuel has been battling VHL disease since he was 17 ...
WABC-TV - Tue, 12 Aug 2014 18:50
|DoD releases list of genetic tests covered by Tricare|
... of 35 laboratory-developed tests covered under a new pilot program, from the better-known BRCA1 and BRCA2 tests for breast cancer and in-utero cystic fibrosis to tests for rare inherited disorders like Lynch syndrome and Von Hippel-Lindau disease.
13WMAZ - Tue, 19 Aug 2014 05:00
|With nine surgeries, a Delhi woman fights a rare disease|
New Delhi: Life cannot be more cruel to Payel Bhattacharya, a patient of Von Hippel-Lindau (VHL), a rare autosomal genetic condition that predisposes individuals to benign and malignant tumors. The 34-year-old, who has already undergone nine surgeries, ...
indiatvnews.com - Wed, 20 Aug 2014 01:15
|Lack of sight doesn't stop pastor from hunting|
But Thomas has a rare genetic disease called Von Hippel-Lindau, in which tumors and fluid-filled sacs or cysts can form in many parts of the body, including the spine, brain and eyes. The doctors found the disease in his eyes when he was 13. "I lost ...
Lewistown Sentinel - Wed, 20 Aug 2014 21:52
|Finding useful biomarkers to predict efficacy of Sunitinib|
Biological markers – or biomarkers – are an area of extreme interest in medicine, as they can be used to diagnose illness, predict the likely course of a disease, or to predict patients' response to a particular intervention. Diagnostic, prognostic ...
ScienceBlog.com (blog) - Fri, 22 Aug 2014 06:18
|Ophthotech's (OPHT) CEO David Guyer on Q2 2014 Results - Earnings Call ...|
We are also planning a trial in proliferative vitreoretinopathy while the National Eye Institute is planning to utilize Fovista in their study for von Hippel-Lindau disease. Turning to our second compound, Zimura. We are also excited about our planned ...
Seeking Alpha (registration) - Sat, 09 Aug 2014 15:07